Accel Instruments and GSI (Gesellschaft fur Schwerionenforschung) are partnering with Siemens Medical Solutions to develop technology for delivering particle therapy. Accel, headquartered in Bergisch Gladbach, Germany, has more than 20 years' experience
Accel Instruments and GSI (Gesellschaft fur Schwerionenforschung) are partnering with Siemens Medical Solutions to develop technology for delivering particle therapy. Accel, headquartered in Bergisch Gladbach, Germany, has more than 20 years' experience in particle accelerator technology. GSI is a government-funded heavy ion research center located in Darmstadt, Germany. Particle therapy treatments utilize fast-moving atomic particles such as ions or protons. Treatments can be focused with pinpoint accuracy, thereby lowering integral dose and reducing toxicity to healthy tissues.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.